

Meaningful Use Program Resources

Research and Tools for Years 2011-2018

January 2019

Quality Reporting Roundtable

Naomi Levinthal, MA, MS, CPHIMS

Practice Manager

levinthn@advisory.com

Ye Hoffman, MS, CPHIMS

Consultant

hoffmany@advisory.com

Bethany Jones, MS, RN, CPHIMS

Senior Consultant

jonesbe@advisory.com

Camille Bridger

Analyst

bridgerc@advisory.com

LEGAL CAVEAT

Advisory Board is a division of The Advisory Board Company. Advisory Board has made efforts to verify the accuracy of the information it provides to members. This report relies on data obtained from many sources, however, and Advisory Board cannot guarantee the accuracy of the information provided or any analysis based thereon. In addition, Advisory Board is not in the business of giving legal, medical, accounting, or other professional advice, and its reports should not be construed as professional advice. In particular, members should not rely on any legal commentary in this report as a basis for action, or assume that any tactics described herein would be permitted by applicable law or appropriate for a given member's situation. Members are advised to consult with appropriate professionals concerning legal, medical, tax, or accounting issues, before implementing any of these tactics. Neither Advisory Board nor its officers, directors, trustees, employees, and agents shall be liable for any claims, liabilities, or expenses relating to (a) any errors or omissions in this report, whether caused by Advisory Board or any of its employees or agents, or sources or other third parties, (b) any recommendation or graded ranking by Advisory Board, or (c) failure of member and its employees and agents to abide by the terms set forth herein.

The Advisory Board Company and the "A" logo are registered trademarks of The Advisory Board Company in the United States and other countries. Members are not permitted to use these trademarks, or any other trademark, product name, service name, trade name, and logo of Advisory Board without prior written consent of Advisory Board. All other trademarks, product names, service names, trade names, and logos used within these pages are the property of their respective holders. Use of other company trademarks, product names, service names, trade names, and logos or images of the same does not necessarily constitute (a) an endorsement by such company of Advisory Board and its products and services, or (b) an endorsement of the company or its products or services by Advisory Board. Advisory Board is not affiliated with any such company.

IMPORTANT: Please read the following.

Advisory Board has prepared this report for the exclusive use of its members. Each member acknowledges and agrees that this report and the information contained herein (collectively, the "Report") are confidential and proprietary to Advisory Board. By accepting delivery of this Report, each member agrees to abide by the terms as stated herein, including the following:

1. Advisory Board owns all right, title, and interest in and to this Report. Except as stated herein, no right, license, permission, or interest of any kind in this Report is intended to be given, transferred to, or acquired by a member. Each member is authorized to use this Report only to the extent expressly authorized herein.
2. Each member shall not sell, license, republish, or post online or otherwise this Report, in part or in whole. Each member shall not disseminate or permit the use of, and shall take reasonable precautions to prevent such dissemination or use of, this Report by (a) any of its employees and agents (except as stated below), or (b) any third party.
3. Each member may make this Report available solely to those of its employees and agents who (a) are registered for the workshop or membership program of which this Report is a part, (b) require access to this Report in order to learn from the information described herein, and (c) agree not to disclose this Report to other employees or agents or any third party. Each member shall use, and shall ensure that its employees and agents use, this Report for its internal use only. Each member may make a limited number of copies, solely as adequate for use by its employees and agents in accordance with the terms herein.
4. Each member shall not remove from this Report any confidential markings, copyright notices, and/or other similar indicia herein.
5. Each member is responsible for any breach of its obligations as stated herein by any of its employees or agents.
6. If a member is unwilling to abide by any of the foregoing obligations, then such member shall promptly return this Report and all copies thereof to Advisory Board.

Resources MU Program Years 2011-2018

The Advisory Board publishes research briefs, tools, and on-demand web conferences on a variety of MU topics. We have grouped these resources into five categories: 1) regulatory analysis; 2) objectives and measures; 3) CQMs; 4) audits; and 5) program management. These resources are presented in descending order from the original publication dates.

Regulatory Analysis

- [2017-2018 Inpatient Quality Reporting and Meaningful Use Modifications](#). This on-demand webconference explains changes to the 2017-2018 IQR and MU reporting requirements finalized in the 2018 IPPS Final Rule (August 2017).
- [2016-2018 MU Modifications](#). This on-demand webconference explains the MU changes finalized in the 2017 OPPI Final Rule (December 2016).
- MACRA. For more on annual Quality Payment Program (i.e., MIPS and APM) requirements, visit this [MACRA topic page](#).
- The Latest Meaningful Use Forecast. This [research brief](#) and [on-demand webconference](#) review the Modified Stage 2 and Stage 3 requirements (October and November 2015).
- [2014 Meaningful Use Reporting Options](#). This report outlines the final rule changes to CEHRT providers can use in 2014 (September 2014).
- [Meaningful Use: The Whiteboard Story](#). Use our poster to see all the Stage 1, Stage 2, and CEHRT requirements together (last updated February 2014).
- [How Stage 2 Raises the Bar on Stage 1 Organizations](#). This research brief outlines changes to Stage 1 (February 2013).
- [Pocket Guide Analysis of Meaningful Use Stage 2](#). Download our easy-to-access pocket guide to see how Stage 1 and Stage 2 compare (February 2013).
- Detailed Analysis of the Final Rule on Stage 2 of Meaningful Use. This [research brief](#) and [archived webconference](#) outline key Stage 2 requirements (September 2012).
- [Final Release of Meaningful Use Stage 1 Criteria: Still a Challenge](#). This research brief reviews the Stage 1 Final Rule (July 2010).

Objectives and Measures

- Modified Stage 2 Health Information Exchange. This [tool](#) reviews how providers can meet Transitions of Care/Health Information Exchange measures in Modified Stage 2 (August 2014).
- [Meaningful Use Stage 2 Preparation: If You Fail to Plan, You Are Planning to Fail](#). This research brief presents data on our interviews with hospitals on how best to prepare for the most challenging objectives (August 2013).

CQMs

- [2017-2018 Inpatient Quality Reporting and Meaningful Use Modifications](#). This on-demand webconference explains changes to the 2017-2018 IQR and MU reporting requirements finalized in the 2018 IPPS Final Rule (August 2017).
- The Hospital 2017 eCQM Reporting Mandate. This [research brief](#) explains the increasing emphasis on electronic reporting of CQMs, and the options EHs have to align reporting efforts between MU and IQR programs in 2017 (October 2016).

- [The Hospital 2016 Electronic CQM Reporting Mandate](#) and [2016 Eligible Professional Quality Reporting](#) These briefs review the provider-specific CQM reporting options in 2016 for MU-alone and in combination with other CMS reporting programs (August 2015 and March 2016, respectively).
- [The 2015 Hospital Clinical Quality Measure Reporting Option](#) and [Navigating the Maze of Ambulatory Clinical Quality Reporting in 2015](#). These briefs review the provider-specific CQM reporting options in 2015 for MU-alone and in combination with other CMS reporting programs (October 2014 and May 2015, respectively).

Audits

- [Meaningful Use Audit Checklists](#). This tool serves as starting point for organizations to develop their own book of evidence (updated March 2015).
- Meaningful Use Audits: Lessons Learned from the Front Line. This [research report](#) and on-demand [webconference](#) details the MU audit landscape and how providers prepare (and in some cases) respond to requests (July 2014 and February 2015).
- [Thrive on the Meaningful Use Audit: Be Prepared, Not Scared](#). This on-demand webconference describes MU audit mechanisms, and presents an Advisory Board member's and Scripps Health's seven steps toward audit success (April 2014).
- [Five Meaningful Use Tips That May Keep You out of an Auditor's Crosshairs](#). This research brief explains CMS' MU audit-risk profiles and how to potentially avoid one with data accuracy and consistency, and anomaly justification (February 2014).
- [Death, Taxes, and Meaningful Use Audits](#). This research report describes the factors that drive audits and reminds providers that there are more than just incentives at risk (July 2012).

Program Management

- The Meaningful Use Risks Posed by Provider Affiliation Changes. This [research brief](#) explains the ways to avoid MU-related consequences when an EP changes organizational affiliation (July 2015).
- [Meaningful Use Incentives and Penalties Calculator](#). This tool enables EHs to estimate MU incentives and payment adjustments (2009).